title: Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.
authors.affiliation: The Cleveland Clinic, Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, 9500 Euclid Ave, Desk R35, Cleveland, OH 44195, USA. advania@ccf.org
authors.forename: Anjali
authors.initials: A
authors.lastname: Advani
authors.forename: Bertrand
authors.initials: B
authors.lastname: Coiffier
authors.forename: Myron S
authors.initials: MS
authors.lastname: Czuczman
authors.forename: Martin
authors.initials: M
authors.lastname: Dreyling
authors.forename: James
authors.initials: J
authors.lastname: Foran
authors.forename: Eva
authors.initials: E
authors.lastname: Gine
authors.forename: Christian
authors.initials: C
authors.lastname: Gisselbrecht
authors.forename: Nicolas
authors.initials: N
authors.lastname: Ketterer
authors.forename: Sunita
authors.initials: S
authors.lastname: Nasta
authors.forename: Ama
authors.initials: A
authors.lastname: Rohatiner
authors.forename: Ingo G H
authors.initials: IG
authors.lastname: Schmidt-Wolf
authors.forename: Martin
authors.initials: M
authors.lastname: Schuler
authors.forename: Jorge
authors.initials: J
authors.lastname: Sierra
authors.forename: Mitchell R
authors.initials: MR
authors.lastname: Smith
authors.forename: Gregor
authors.initials: G
authors.lastname: Verhoef
authors.forename: Jane N
authors.initials: JN
authors.lastname: Winter
authors.forename: Joseph
authors.initials: J
authors.lastname: Boni
authors.forename: Erik
authors.initials: E
authors.lastname: Vandendries
authors.forename: Mark
authors.initials: M
authors.lastname: Shapiro
authors.forename: Luis
authors.initials: L
authors.lastname: Fayad
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005060:Europe; D005260:Female; D006801:Humans; D000922:Immunotoxins / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D000080045:Inotuzumab Ozogamicin; D053208:Kaplan-Meier Estimate; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D010865:Pilot Projects; D051918:Sialic Acid Binding Ig-like Lectin 2 / Q000276:immunology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C497867:CD22 protein, human; D000922:Immunotoxins; D051918:Sialic Acid Binding Ig-like Lectin 2; D000080045:Inotuzumab Ozogamicin